Intra-Cellular Therapies Inc (NASDAQ:ITCI)
| 43.04 Delayed Data As of Jan 14 |  +2.07 / +5.05%Today’s Change | 28.40 Today|||52-Week Range 55.20 | -17.77% Year-to-Date |
Latest ITCI News | Press Releases
| Penbrook Management LLC Buys Cohu Inc, Kulicke & Soffa Industries Inc, PubMatic Inc, Sells ... Jan 10 / GuruFocus News - Paid Partner Content | Why Intra-Cellular Therapies Took a Big Hit Today Jan 04 / MotleyFool.com - Paid Partner Content |
Today’s Trading
| Previous close | 40.97 |
| Today’s open | 40.59 |
| Day’s range | 40.33 - 43.14 |
| Volume | 44,870 |
| Average volume (3 months) | 780,972 |
| Market cap | $4.0B |
Data as of 4:00pm ET, 01/14/2022
Growth & Valuation
| Earnings growth (last year) | -20.52% |
| Earnings growth (this year) | -7.01% |
| Earnings growth (next 5 years) | +2.50% |
| Revenue growth (last year) | +37,537.11% |
| P/E ratio | NM |
| Price/Sales | 98.08 |
| Price/Book | 5.27 |
Competitors
Data as of 4:00pm ET, 01/14/2022
Financials
| Next reporting date | March 2, 2022 |
| EPS forecast (this quarter) | -$1.01 |
| Annual revenue (last year) | $22.8M |
| Annual profit (last year) | -$227.0M |
| Net profit margin | -995.07% |
Profile
Sector Health Technology |
Industry Biotechnology |
No executives to display |
Corporate headquarters New York, New York |
Forecasts
